According to filings with the U.S. Securities and Exchange Commission, Quadrant Biosciences is raising $25,425,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Richard Uhlig played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Quadrant Biosciences
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinsons disease, and mTBI, through the application of the Clarifi epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.

To learn more about Quadrant Biosciences, visit http://quadrantbiosciences.com/

Contact:
Richard Uhlig, Chief Executive Officer
607-227-4400
https://www.linkedin.com/in/richard-uhlig-4a3a0b100/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.